Treatment of metastatic colorectal Cancer Aflibercept/FOLFIRI can be widely used in the second Therapy Line

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷 / 06期
关键词：
FLUOROURACIL; LEUCOVORIN; IRINOTECAN; PLACEBO;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358 / 358
页数：1
相关论文
共 50 条
  • [1] FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer
    Carola, Candice
    Ghiringhelli, Francois
    Kim, Stefano
    Andre, Thierry
    Barlet, Juliette
    Bengrine, Leila
    Marijon, Helene
    Garcia, Marie Line
    Borg, Christophe
    Dainese, Linda
    Steuer, Nils
    Larsen, Annette K.
    De Gramont, Aimery
    Chibaudel, Benoist
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer
    Denda, Tadamichi
    Sakai, Daisuke
    Hamaguchi, Tetsuya
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Sunaga, Yoshinori
    Ziti-Ljajic, Samira
    Brillac, Claire
    Yoshino, Takayuki
    CANCER SCIENCE, 2019, 110 (03) : 1032 - 1043
  • [3] Folfiri-aflibercept vs folfiri-bevacizumab as second line treatment of RAS mutated metastatic colorectal cancer in real practice
    Ottaiano, A.
    Capozzi, M.
    De Divitiis, C.
    Cassata, A.
    De Stefano, A.
    Tafuto, S.
    Avallone, A.
    Nasti, G.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Metastatic colorectal Cancer Ramucirumab plus FOLFIRI as Second Line Treatment
    Lichert, Frank
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1145 - 1145
  • [5] A Comparison of Folinic Acid, Fluorouracil and Irinotecan (FOLFIRI) plus Bevacizumab and FOLFIRI plus Aflibercept as Second-line Treatment for Metastatic Colorectal Cancer
    Jo, H.
    Lee, M-S
    Lee, Y-P
    Kim, H.
    Hong, J. Y.
    Lee, J.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Lim, H. Y.
    Kang, W. K.
    Kim, S. T.
    CLINICAL ONCOLOGY, 2022, 34 (08) : E323 - E328
  • [6] Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
    Ottaiano, Alessandro
    Capozzi, Monica
    Tafuto, Salvatore
    De Stefano, Alfonso
    De Divitiis, Chiara
    Romano, Carmela
    Avallone, Antonio
    Nasti, Guglielmo
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [7] Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
    Kim, Jinchul
    Kim, Hana
    Hong, Jung Yong
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kang, Won Ki
    Kim, Seung Tae
    JOURNAL OF CANCER, 2021, 12 (02): : 460 - 466
  • [8] Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
    Ottaiano, Alessandro
    Scala, Stefania
    Santorsola, Mariachiara
    Trotta, Anna Maria
    D'Alterio, Crescenzo
    Portella, Luigi
    Clemente, Ottavia
    Nappi, Anna
    Zanaletti, Nicoletta
    De Stefano, Alfonso
    Avallone, Antonio
    Granata, Vincenza
    Notariello, Carmen
    Luce, Amalia
    Lombardi, Angela
    Picone, Carmine
    Petrillo, Antonella
    Perri, Francesco
    Tatangelo, Fabiana
    Di Mauro, Annabella
    Albino, Vittorio
    Izzo, Francesco
    Rega, Daniela
    Pace, Ugo
    Di Marzo, Massimiliano
    Chiodini, Paolo
    De Feo, Gianfranco
    Del Prete, Paola
    Botti, Gerardo
    Delrio, Paolo
    Caraglia, Michele
    Nasti, Guglielmo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [9] Complete Metabolic Response Assessed by FDG PET/CT to FOLFIRI-Aflibercept in Second-Line Treatment of Metastatic Colorectal Cancer
    Amrane, Karim
    Ollivier, Luc
    Salaun, Pierre-Yves
    Metges, Jean-Philippe
    Abgral, Ronan
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (07) : 578 - 579
  • [10] Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
    Lavacchi, Daniele
    Roviello, Giandomenico
    Giommoni, Elisa
    Dreoni, Lorenzo
    Derio, Silvia
    Brugia, Marco
    Amedei, Amedeo
    Pillozzi, Serena
    Antonuzzo, Lorenzo
    CANCERS, 2021, 13 (15)
12345